WVE Stock Analysis: Wave Life Sciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.204m USD | 12M Return: -9.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.6M
Qual. Beats: 1
Rev. Trend: 1.7%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company headquartered in Singapore that uses its proprietary PRISM platform to design and develop RNA-based medicines. Its pipeline includes candidates targeting alpha-1 antitrypsin deficiency (WVE-006), obesity (WVE-007), liver disease (WVE-008), Duchenne muscular dystrophy (WVE-N531), and Huntingtons disease (WVE-003). The company operates under a partnership-heavy business model, with collaboration agreements with GlaxoSmithKline, Takeda Pharmaceutical, and Asuragen supporting research, development, and commercialization of its oligonucleotide programs. Founded in 2012 and listed on NASDAQ since 2015, Wave is classified within the GICS Pharmaceuticals sub-industry and currently carries a small-cap market valuation of approximately $1.2 billion.
- WVE-006 alpha-1 antitrypsin deficiency clinical data readout approaches
- GSK and Takeda collaborations deliver milestone payments
- Equity dilution risk as clinical-stage cash burn accelerates
| Net Income: -183.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA 31.47 > 1.0 |
| NWC/Revenue: 712.3% < 20% (prev 162.6%; Δ 549.8% < -1%) |
| CFO/TA -0.31 > 3% & CFO -182.4m > Net Income -183.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (200.2m) vs 12m ago 23.16% < -2% |
| Gross Margin: 87.67% > 18% (prev 31.17%; Δ 56.50% > 0.5%) |
| Asset Turnover: 16.47% > 50% (prev 36.39%; Δ -19.92% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 561.3m - Total Current Liabilities 49.8m) / Total Assets 583.5m |
| B: -2.32 (Retained Earnings -1.35b / Total Assets 583.5m) |
| C: -0.42 (EBIT TTM -183.6m / Avg Total Assets 435.9m) |
| D: 7.13 (Book Value of Equity 511.7m / Total Liabilities 71.8m) |
| Altman-Z'' = 2.85 = A |
As of July 08, 2026, the stock is trading at USD 6.38 with a total of 2,738,218 shares traded. Over the past week, the price has changed by +12.32%, over one month by +11.93%, over three months by -10.14% and over the past year by -9.63%.
Current recommended Stop Loss: 5.90 (which is 7.5% or 1.5 ATR below the current price).
Wave Life Sciences has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy WVE.
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.9 | 243.9% |
P/S = 16.7754
P/B = 2.192
Revenue TTM = 71.8m USD
EBIT TTM = -183.6m USD
EBITDA TTM = -174.6m USD
Long Term Debt = 7.39m USD (estimated: total debt 15.7m - short term 8.33m)
Short Term Debt = 8.33m USD (from shortTermDebt, last quarter)
Debt = 15.7m USD (from shortLongTermDebtTotal, last quarter) (leases 15.7m already included)
Net Debt = -528.9m USD (calculated: Debt 15.7m - CCE 544.6m)
Enterprise Value = 675.6m USD (1.20b + Debt 15.7m - CCE 544.6m)
Interest Coverage Ratio = unknown (Ebit TTM -183.6m / Interest Expense TTM 0.0)
EV/FCF = -3.68x (Enterprise Value 675.6m / FCF TTM -183.3m)
FCF Yield = -27.14% (FCF TTM -183.3m / Enterprise Value 675.6m)
FCF Margin = -255.4% (FCF TTM -183.3m / Revenue TTM 71.8m)
Net Margin = -255.7% (Net Income TTM -183.6m / Revenue TTM 71.8m)
Gross Margin = 87.67% ((Revenue TTM 71.8m - Cost of Revenue TTM 8.85m) / Revenue TTM)
Gross Margin QoQ = none% (prev 86.88%)
Tobins Q-Ratio = 1.16 (Enterprise Value 675.6m / Total Assets 583.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 15.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -145.0m (EBIT -183.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.26 (Total Current Assets 561.3m / Total Current Liabilities 49.8m)
Debt / Equity = 0.03 (Debt 15.7m / totalStockholderEquity, last quarter 511.7m)
Debt / EBITDA = 3.03 (negative EBITDA) (Net Debt -528.9m / EBITDA -174.6m)
Debt / FCF = 2.88 (negative FCF - burning cash) (Net Debt -528.9m / FCF TTM -183.3m)
Total Stockholder Equity = 325.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.11% (Net Income -183.6m / Total Assets 583.5m)
RoE = -56.41% (Net Income TTM -183.6m / Total Stockholder Equity 325.4m)
RoCE = -55.16% (EBIT -183.6m / Capital Employed (Equity 325.4m + L.T.Debt 7.39m))
RoIC = -26.94% (negative operating profit) (NOPAT -145.0m / Invested Capital 538.5m)
WACC = 13.16% (E(1.20b)/V(1.22b) * Re(13.33%) + D(15.7m)/V(1.22b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.33% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 32.60%
[DCF] Fair Price = unknown (Cash Flow -183.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.27 | # QB: 1
Revenue Correlation: 1.72 | Revenue CAGR: 0.78% | SUE: 1.31 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.30 | Chg30d=+1.52% | Revisions=+36% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.31 | Chg30d=+2.60% | Revisions=+55% | Analysts=11
EPS current Year (2026-12-31): EPS=-0.84 | Chg30d=+4.29% | Revisions=+75% | GrowthEPS=+30.8% | GrowthRev=+38.4%
EPS next Year (2027-12-31): EPS=-1.08 | Chg30d=+2.18% | Revisions=+31% | GrowthEPS=-29.4% | GrowthRev=-12.9%
[Analyst] Revisions Ratio: +61% (up=29, down=6)